November 2016, Vol. 5, No. 9

← Back to Issue

Providing Practical Information to Promote Targeted, Effective, and Personalized Treatments


Letter to Our Readers

Dear Colleague,

With every issue, all of us on the editorial staff of Personalized Medicine in Oncology (PMO) strive to provide members of multidisciplinary oncology teams practical information about research advances and improvements within the personalized medicine spectrum that allow for more targeted and effective treatments.

We are pleased to offer a continuing education opportunity entitled “Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.” This activity explores the role of immune checkpoint inhibitors in the treatment of an increasing range of solid tumors and hematologic malignancies as well as the use of predictive molecular biomarkers. In addition, it examines the value proposition associated with the use of immune checkpoint inhibitors in terms of costs and management of adverse events.

We offer insights from Steven Sandler, MD, on the 2016 revisions to the World Health Organization’s classification of myeloid neoplasms and acute leukemia in his article entitled “Understanding the Current Classification Criterion and Prognosis Models for the Myelodysplastic Syndromes and Dysplastic Cytopenias of Undetermined Significance as a Paradigm for Personalized Medicine.”

To enhance reader learning, we present a case study from Dr Steven Sorscher and colleagues entitled “A One Pathway ‘Two-Different Hit’ Hypothesis: Symbiosis in Transformation.” The authors discuss a patient with pancreatic cancer and PALB2 and BRCA2 alterations.

Coverage of important topics from the European Society for Medical Oncology is included in this issue, as well as an article from the Palliative Care in Oncology Symposium on managing immune-related toxicities.

Thank you for your readership. On behalf of the Editorial Board, it is our pleasure to serve you well in our quest to implement the new processes of personalized medicine.


Coeditor in Chief
Personalized Medicine in Oncology

ESMO 2016 - November 10, 2016

Practice-Changing Study Shows Niraparib Extends Progression-Free Survival in Platinum-Sensitive Ovarian Cancer

Maintenance therapy with niraparib, an investigational oral PARP inhibitor, significantly prolonged progression-free survival (PFS) in patients with recurrent platinum-sensitive ovarian cancer regardless of BRCA status and homologous recombination deficiency (HRD) status. “This is a breakthrough for patients with ovarian cancer. We have never seen such large benefits in progression-free survival [ Read More ]

ESMO 2016 - November 10, 2016

Pembrolizumab plus Chemotherapy Doubled Response Rate Over Chemotherapy Alone in NSCLC

With the success of programmed death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors in non–small cell lung cancer (NSCLC), attention has focused on how best to combine these immunotherapies, and one question has been whether they can be safely and effectively combined with standard chemotherapy. Combining pembrolizumab with a standard [ Read More ]